Skip to main content
Sign In

Clinical Research Studies

Prevention and Intervention Trials for Patients

The Barbara Davis Center for Diabetes, located at the University of Colorado Anschutz Medical Campus, is actively involved in clinical research. The research division has several on-going studies, as well as ones that are op​n for enrollment. These studies are all dedicated to the pursuit of preventing diabetes in high-risk patients as well as clinical intervention with those already diagnosed with Type 1 diabetes.

The studies listed below are currently enrolling eligible participants.

The BDC is a nationally recognized diabetes research center. 

Man using telemedicine

​​​Currently Enrolling Studies for Children with Diabetes

COMIRB number: PTL-900740/ approval date: Jan 22, 2014

YSI Feasibility Study of the Dexcom™ CGM System in Adults and Pediatrics with Diabetes Mellitus

Inclusion criteria:

  • Children ages 6-17 with Type 1 Diabetes who are willing to wear a Dexcom system and participate in up to an 8 hour clinic session.

Principal Investigators: Peter Chase

Study Coordinator: Emily Westfall

COMIRB number: 14-0347/ approval date: May 11, 2014

FL3X – Flexible Lifestyle 3mpoweing Change. Purpose of this research study is to develop new ways of helping teens manage their diabetes.

Inclusion criteria:

  • Patient at the Barbara Davis Center.

  • Between 13  and 16 years old

  • Type 1 diabetes for longer than 1 year

  • HbA1c between 8-13%

Principal Investigators: David Maahs

Study Coordinator: Franziska Bishop, 303-724-6764

Currently Enrolling Studies for Children and Adults with Type 1 Diabetes
​COMIRB number: 06-0420
Twins with Type 1 Diabetes Research Study
Goal: To determine the relative contribution of genetic and environmental factors to the early stages of and progression type 1 diabetes and related autoimmune diseases.
Main inclusion/exclusion criteria:
  • Twins affected by type 1 diabetes and unaffected twins, non-twin siblings and parents.
  • Type 1 diabetes in the affected participant is defined as onset < 40 years old and the use of daily insulin therapy within one year of diagnosis.
  • Participants must be between 6 months and 80 years old.
​​​Duration of Participation: The first visit will take about 30 minutes. Depending on the results of the tests, participants will be asked to come in for a visit every 6-24 months. The study will continue until the participant withdraws or until funding is stopped.
Compensation provided.
Principal Investigator: Andrea Steck​
Study Coordinator: Alexandra Fouts​, 303-724-6774
​COMIRB number: 11-1144/approval date: Sep 17, 2014
The role of gut bacteria in the development of Type 1 Diabetes
Goal: Investigate the involvement of bacteria living in the intestine in the process leading to the appearance of autoantibodies against insulin producing cells and Type 1 Diabetes
Inclusion criteria:
  • Patients diagnosed with Type 1 Diabetes in the last 6 months
  • Non-diabetic subjects with autoantibodies
  • Autoantibody negative first degree relatives of patients with Type 1 Diabetes or subjects with autoantibodies
  • Between 1 and 45 years of age
Principal Investigator: Danny Zipris
Study Coordinators: Aimon Alkanani or James Needell​, 303-724-6820

COMIRB number: 13-2652/ approval date: Dec 11, 2013

Gleevec-  Safety and Efficacy of Imatinib for Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus

Goal: The purpose of this trial is to test whether a drug called Gleevec (Imatinib) will slow or halt destruction of the beta cells in the pancreas.

Inclusion criteria:

  • Ages 12-45 (Adults and then children)

  • Within 100 days of diagnosis with type 1 diabetes

  • Confirmed type 1 diabetes

Principal Investigator: Peter Gottlieb

Study Coordinator: Allison Schauwecker, 303-724-8615

COMIRB number: 13-1457/ approval date: May 24, 2013

Outpatient Reduction of Nocturnal Hypoglycemia By Using algorithms and Pump Suspension

Inclusion Criteria:

Children and adults with Type 1 Diabetes who use wear an insulin pump and CGM and are interested in using a computer to help regulate blood sugars overnight at home.

Principal Investigators: David Maahs & Peter Chase

Study Coordinator: Dena Gottesman​​

COMIRB number: 13-2759/ approval date: Dec 13, 2013

Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Lipohypertrophy Study

Inclusion Criteria:

  • Children and adults (12-45 y/o) with Type 1 Diabetes who have lipohypertrophy (≥3cm) and wear an insulin pump who are willing to wear two Dexcoms over a 4 week study period.

Principal Investigator: David Maahs

Study Coordinator: Laurel Messer

​​​COMIRB number: 13-2668/ approval date: Oct 25, 2013

Early Diagnosis of Change in GFR in Adolescents with Type 1 Diabetes by Iohexol Clearance.

Criteria Inclusion:

  • have type 1 diabetes

  • between ages 12-25

  • normal blood pressure

  • normal kidney function

Principal Investigator: David Maahs

Study Coordinator: Vicky Gage, 303-724-8369

​Currently Enrolling Studies for Adults with Type 1 Diabetes

COMIRB number: 13-1408/ approval date: May 25, 2013

The Effect of Methyldopa on MHC class II antigen presentation in type 1 diabetes

Inclusion Criteria:

  • Ages 18-46 years old

  • Diagnosed with type 1 diabetes within the last 2 years

  • Be willing to take methyldopa, an oral medication, for 6 weeks

  • Participate in 6 visits at the Barbara Davis Center over 3 months

Principal Investigator: Aaron Michels

Study Coordinator: Aimon Alkanan

COMIRB number: 13-2457/ approval date: Nov 11, 2013

PERL: Preventing Early Renal Loss in Diabetes.

Adult clinical trial to determine whether lowering serum uric acid by means of allopurinol early in the course of kidney disease may be effective in preventing or slowing the decline of renal function in T1D patients.

Inclusion Criteria

  • Diagnosed with type 1 diabetes before age 35

  • T1D for >8 years

  • Ages 18-65

  • History or presence of microalbuminuria

  • Estimated GFR (eGFR) between 45-99.9

  • Serum Uric Acid >4.5 mg/dl

Principal Investigator: David Maahs

Study Coordinator: Vicky Gage, 303-724-8369

COMIRB number: 14-0143 / approval date April 02, 2014

Pfizer (RN168): A Phase I Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of PF-06342674 (RN168) in Adults with Type 1 Diabetes

Goal: Assess the effect of weekly subcutaneous injections bi-weekly for 10 weeks.

Inclusion Criteria: 
  • Ages 18 and older
  • Body Mass Index 18-32
  • Diagnosed with Type 1 Diabetes within the last 2 years

Principal Investigator: Peter Gottlieb

Study Coordinator: Allison Schauwecker, 303-724-8615

COMIRB number: 13-2824/ approval date: Dec 18, 2013

Exenatide (Bydureon)

Goal: The goal of this trial is to test whether a drug called Exenatide (Bydureon), typically used to treat type 2 diabetes, will help people with type 1 diabetes improve their blood glucose levels.

Inclusion Criteria:

  • Ages 18-60

  • Confirmed T1D for at least 2 years

  • Insulin requirements of  no more than 0.9 units/kg/day

  • No DKA previous 6 months

  • A1c less than or equal to 9.0%

Principal Investigator: Peter Gottlieb

Study Coordinator: Allison Schauwecker, 303-724-8615